Rickets & osteomalacia

1. High-Yield Summary

Rickets and osteomalacia represent metabolic bone disorders characterized by deficient mineral deposition within newly synthesized organic skeletal matrix. Rickets specifically affects the cartilaginous growth plate (physis) in skeletally immature individuals, producing physeal widening, disorganized endochondral ossification, and progressive limb deformities. Osteomalacia occurs in both mature and immature bone, characterized by defective mineralization of osteoid seams throughout cortical and trabecular remodeling units, leading to bone pain, proximal myopathy, and cortical pseudofractures.

• Pathophysiological Bifurcation: The disease spectrum divides strictly into calcipenic etiologies (calcium deficiency, vitamin D deficiency, gastrointestinal malabsorption, and vitamin D-dependent rickets types 1 and 2, driven by secondary hyperparathyroidism) and phosphopenic etiologies (renal phosphate wasting mediated predominantly by excess fibroblast growth factor 23 [FGF23], such as X-linked hypophosphatemia [XLH], tumor-induced osteomalacia [TIO], and autosomal forms, or intrinsic tubular defects such as Fanconi syndrome).
• Hallmark Diagnostic Signatures: Elevated serum alkaline phosphatase (ALP) is the universal, indispensable biomarker of active disease and osteoblast turnover. Calcipenic rickets presents with low-to-normal serum calcium, secondary hyperparathyroidism, low urinary calcium, and elevated ALP. Phosphopenic rickets presents with normal calcium, normal-to-mildly elevated parathyroid hormone (PTH), profound hypophosphatemia, elevated or inappropriately normal FGF23, and markedly depressed tubular maximum reabsorption of phosphate per glomerular filtration rate (TmP/GFR).
• Pathognomonic Imaging: Pediatric plain radiographs demonstrate metaphyseal cupping, flaring, fraying, and physeal widening at rapidly growing anatomical regions (distal femur, proximal tibia, distal radius/ulna). Adult osteomalacia demonstrates diffuse osteopenia, coarsened trabecular architecture, biconcave (“codfish”) vertebrae, and pathognomonic Looser zones (Milkman pseudofractures) running perpendicular to cortex on the medial femoral neck, medial subtrochanteric shaft, pubic rami, and scapular border.
• The Cardinal Orthopaedic Surgical Mandate: Corrective osteotomy is strictly contraindicated during active, metabolically uncompensated disease. Executing osteotomies through unmineralized osteoid precipitates catastrophic nonunion, hardware loosening, cutting-out in softened bone, and rapid deformity recurrence. Elective surgery must be deferred until serum ALP, calcium, phosphate, and PTH have normalized and radiographic reconstitution of the zone of provisional calcification has been documented for a minimum of 3 to 6 months.
• Targeted Biological Paradigm Shift: The introduction of burosumab, a fully human recombinant monoclonal antibody against FGF23, has revolutionized the treatment of XLH and unresectable TIO, achieving superior physeal healing, linear growth velocity, and phosphate normalization while eliminating the severe nephrocalcinosis risks associated with high-dose oral phosphate and calcitriol therapy.

2. Anatomy

Anatomical consideration of rickets and osteomalacia requires precise knowledge of epiphyseal growth plate histomorphology, cortical bone remodeling dynamics, physeal vascular architecture, and the lower extremity mechanical axis.

Epiphyseal Growth Plate Histomorphology

The pediatric growth plate (physis) is divided into four distinct histological zones progressing from the epiphysis toward the metaphysis:

• Reserve (Resting) Zone: Contains spherical, quiescent chondrocytes embedded in a type II collagen and proteoglycan-rich extracellular matrix. These cells maintain storage reserves of lipids and glycogen and do not actively proliferate or mineralize.
• Proliferative Zone: Flattened chondrocytes divide longitudinally to form organized columns (isogenous groups). Cellular division and type II/IX/XI collagen synthesis in this zone drive longitudinal bone elongation.
• Hypertrophic Zone: Chondrocytes cease dividing and undergo dramatic 5- to 10-fold volumetric enlargement, switching phenotypic expression to type X collagen, alkaline phosphatase, and matrix vesicles. This zone is subdivided into the maturation, degenerative, and provisional calcification zones.
• Zone of Provisional Calcification (The Epicenter of Rachitic Pathology): Under physiological conditions, terminal hypertrophic chondrocytes secrete matrix vesicles containing calcium, inorganic phosphate, and tissue-nonspecific alkaline phosphatase (TNAP). TNAP cleaves inorganic pyrophosphate (a mineralization inhibitor), allowing calcium and phosphate to nucleate into hydroxyapatite crystals within the intercolumnar longitudinal septa. This provisional calcification triggers terminal chondrocyte apoptosis, metaphyseal capillary ingrowth, osteoclast recruitment to resorb calcified cartilage septa, and osteoblast recruitment to lay down woven bone (primary spongiosa).

In rickets, mineralization within the zone of provisional calcification fails due to insufficient calcium, phosphate, or both. As a direct consequence, the biological trigger for terminal chondrocyte apoptosis is aborted. Hypertrophic chondrocytes do not die; instead, they persist and continue to accumulate in lengthened, disorganized, distorted columns. The physis dramatically expands in both axial height and transverse diameter (up to 5 to 10 times normal thickness). Metaphyseal vascular loops cannot penetrate uncalcified cartilage, creating the classic radiographic triad of physeal widening, metaphyseal cupping, and brush-like fraying.

Cortical Bone Remodeling and Osteoid Seams

In the mature skeleton and cortical bone, osteomalacia manifests as a failure of osteoid mineralization within bone remodeling units (basic multicellular units [BMUs]):

• Osteoid Seam Dimensions: Following osteoclastic resorption, osteoblasts deposit an organic matrix composed predominantly of type I collagen, osteocalcin, osteopontin, and osteonectin (osteoid). Normally, the osteoid seam measures less than 12 to 14 µm in width, with a mineralization lag time (MLT) of approximately 20 days.
• Osteomalacic Matrix Accumulation: In osteomalacia, osteoblasts continue to synthesize organic matrix at normal or accelerated rates, but mineralization is arrested. Consequently, unmineralized osteoid seams thicken pathologically (>20 to 30 µm) and cover over 20% to 50% of the total trabecular and Haversian surface area (normal osteoid surface is <5%). Mineralization lag time extends beyond 100 days.
• Histomorphometric Signature: On undecalcified bone biopsy with double tetracycline labeling, the normal discrete, dual parallel fluorescent lines under ultraviolet microscopy are lost, replaced by single, wide, blurred, or completely absent fluorochrome bands.

Vascular Supply to the Physis and Metaphysis

The physis receives a dual, non-anastomosing blood supply:

• Epiphyseal Arterial Supply: Arises from periarticular arterial rings, enters the epiphysis, and arborizes into capillary networks terminating at the germinal side of the proliferative zone. This supply provides oxygen and nutrients for cellular division and remains intact in rickets, enabling uninterrupted chondrocyte proliferation.
• Metaphyseal Arterial Supply: Arises from terminal branches of the nutrient artery and periosteal system, forming vascular hairpin loops that abut the zone of provisional calcification. In rickets, endothelial invasion of chondrocyte lacunae is blocked by the absence of provisional calcification. These metaphyseal capillary loops become ectatic, engorged, and tortuous, accounting for the clinical warmth and swelling observed at rachitic joints.

Mechanical Axis and Lower Extremity Alignment

The mechanical axis of the lower extremity (Mikulicz line) runs from the center of the femoral head through the intercondylar midpoint of the knee to the center of the tibial plafond:

• Mechanical Axis Deviation (MAD): Normally passes within 3 to 8 mm medial to the knee center. In rickets, softened metaphyseal bone and structurally incompetent physes deform under gravitational load and muscular vector forces.
• Genu Varum (Bow Legs): Typically emerges as infants initiate weight-bearing ambulation (12 to 18 months). Ground reaction forces medial to the knee create an adduction moment, concentrating compressive load across the medial physis, driving medial mechanical axis shift, lateral ligamentous laxity, and lateral thrust during the stance phase of gait.
• Genu Valgum and Windswept Deformities: In older children (especially those with XLH) or following asymmetric physeal loading, deformities may manifest as progressive genu valgum (intermalleolar distance >7.5 cm) or windswept lower extremities (valgus deformity in one limb combined with varus deformity in the contralateral limb).
• Coxa Vara: Excessive unmineralized osteoid within the proximal femoral neck physis decreases the femoral neck-shaft angle to <120°, shortening the abductor lever arm and generating a Trendelenburg or waddling gait.

3. Pathogenesis

Mineralization of the skeleton requires homeostatic maintenance of circulating extracellular calcium and inorganic phosphate concentrations within a narrow physiological window to maintain an adequate calcium-phosphate ion product ([Ca] × [PO4]).

Calcium-Sensing Receptor and PTH Regulation

The extracellular calcium-sensing receptor (CaSR), a G-protein-coupled receptor on parathyroid chief cells, continuously monitors ionized calcium levels. Reductions in ionized calcium relieve tonic CaSR inhibition, prompting immediate secretion of parathyroid hormone (PTH):

• Renal Actions of PTH: PTH binds the PTH1R receptor in the renal distal tubule to stimulate calcium reabsorption via apical TRPV5 channels. Simultaneously, in the proximal convoluted tubule, PTH stimulates endocytic internalization and lysosomal degradation of sodium-phosphate cotransporters (NaPi-IIa and NaPi-IIc), producing phosphaturia.
• Enzymatic Induction: PTH strongly stimulates renal 25-hydroxyvitamin D 1-alpha-hydroxylase (CYP27B1) expression in the proximal tubule, accelerating production of active 1,25-dihydroxyvitamin D [1,25(OH)2D].
• Secondary Hyperparathyroidism Cascade: In calcipenic rickets, sustained hypocalcemia produces persistent, marked PTH elevations. Although PTH successfully defends serum calcium near the lower physiological limit, it does so at the expense of massive renal phosphate wasting, leading to hypophosphatemia. Thus, impaired mineralization in calcipenic rickets is ultimately driven by the secondary drop in the calcium-phosphate product.

Vitamin D Metabolic Pathway and Receptor Signaling

Vitamin D metabolism involves sequential, tightly orchestrated cutaneous photolysis and hepatic/renal hydroxylations:

• Cutaneous Photolysis: Solar ultraviolet B radiation (UVB, 290–315 nm) photolyzes epidermal 7-dehydrocholesterol to previtamin D3, which undergoes temperature-dependent isomerization to cholecalciferol (vitamin D3).
• Hepatic 25-Hydroxylation: Vitamin D3 and dietary ergocalciferol (D2) circulate bound to vitamin D-binding protein (DBP) to the liver, where microsomal cytochrome P450 2R1 (CYP2R1) hydroxylates them into 25-hydroxyvitamin D [25(OH)D, calcidiol]. Circulating 25(OH)D has a 2- to 3-week half-life and represents the accurate measure of total body vitamin D stores.
• Renal 1-Alpha-Hydroxylation: In proximal tubular mitochondria, CYP27B1 adds a second hydroxyl group to form 1,25(OH)2D (calcitriol), the high-affinity biological ligand. CYP27B1 is upregulated by PTH and hypophosphatemia, and downregulated by FGF23 and hypercalcemia.
• Catabolic Pathway: Cytochrome P450 24A1 (CYP24A1, 24-hydroxylase) inactivates both 25(OH)D and calcitriol into water-soluble calcitroic acid for biliary excretion.
• VDR Nuclear Actions: Calcitriol binds the nuclear Vitamin D Receptor (VDR), heterodimerizes with the Retinoid X Receptor (RXR), and binds vitamin D response elements (VDRE) in promoter regions of target genes. In enterocytes, this upregulates apical calcium channel TRPV6, intracellular calbindin-D9k, and basolateral calcium ATPase (PMCA1b), tripling intestinal calcium absorption and stimulating phosphate uptake via apical NaPi-IIb cotransporters.

The FGF23 / Klotho Axis and Renal Phosphate Wasting

Fibroblast Growth Factor 23 (FGF23) is a 32-kDa phosphaturic hormone synthesized and secreted by osteocytes and mature osteoblasts in response to elevated phosphate, calcitriol, and extracellular calcium:

• Receptor Complex: Circulating FGF23 acts on renal proximal tubular epithelial cells by binding to FGFR1c in the presence of its mandatory, transmembrane co-receptor, alpha-Klotho.
• Phosphaturic Mechanism: Activation of the FGFR1c-Klotho complex activates downstream ERK1/2 and SGK1 signaling cascades, triggering the rapid endocytosis, retrieval, and lysosomal degradation of apical sodium-phosphate cotransporters NaPi-IIa (SLC34A1) and NaPi-IIc (SLC34A3). This shuts down tubular phosphate reabsorption, causing profound urinary phosphate wasting.
• Suppression of Calcitriol Synthesis: Simultaneously, FGF23 directly suppresses renal CYP27B1 transcription and upregulates CYP24A1 catabolism. Consequently, serum 1,25(OH)2D levels remain inappropriately normal or frankly low despite profound hypophosphatemia, preventing compensatory intestinal phosphate absorption and compounding the systemic phosphate deficit.

Molecular Genetics of Inherited and Acquired Rickets

Genetic rickets arises from targeted mutations affecting vitamin D activation, vitamin D receptor signaling, or FGF23 regulatory machinery:

• PHEX Mutations (X-Linked Hypophosphatemia [XLH]): Inactivating mutations in the PHEX gene (phosphate-regulating endopeptidase homolog, X-linked, locus Xp22.1) represent the most common cause of inherited rickets (1 in 20,000 live births). PHEX loss of function in osteocytes dysregulates local feedback loops, driving excessive autonomous synthesis and secretion of intact FGF23.
• FGF23 Cleavage-Resistant Mutations (ADHR): Autosomal Dominant Hypophosphatemic Rickets involves missense mutations replacing arginine residues at the consensus furin-cleavage site (R176Q, R176W, R179Q, R179W). The mutant FGF23 cannot be enzymatically cleaved into inactive fragments, causing circulating intact FGF23 accumulation, frequently unmasked or exacerbated by iron deficiency.
• DMP1 and ENPP1 Mutations (ARHR1 and ARHR2): Inactivating mutations in dentin matrix acidic phosphoprotein 1 (DMP1) or ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) induce Autosomal Recessive Hypophosphatemic Rickets through osteocytic FGF23 hypersecretion.
• Tumor-Induced Osteomalacia (TIO): A paraneoplastic syndrome caused by benign mesenchymal neoplasms (predominantly phosphaturic mesenchymal tumors [PMTs]) that autonomously overexpress and secrete intact FGF23, driving severe acquired hypophosphatemic osteomalacia.
• CYP27B1 Mutations (VDDR Type 1A): Autosomal recessive loss-of-function mutations in 1-alpha-hydroxylase prevent conversion of 25(OH)D to 1,25(OH)2D, producing severe early-onset calcipenic rickets with normal 25(OH)D but undetectable 1,25(OH)2D.
• VDR Mutations (VDDR Type 2A): Inactivating mutations in the vitamin D receptor gene prevent cellular response to calcitriol, causing severe early-onset rickets characterized by markedly elevated serum 1,25(OH)2D levels and total alopecia (alopecia totalis/universalis) due to loss of VDR-dependent hair follicle cycling.

Biochemical Failure of Hydroxyapatite Nucleation

Hydroxyapatite crystal nucleation ($Ca_{10}(PO_4)_6(OH)_2$) requires a critical extracellular solubility product of ionic calcium and inorganic phosphate (typically [Ca] × [PO4] >35 mg²/dL²). When circulating phosphate or ionized calcium drops below critical thresholds, crystallization is arrested. Tissue-nonspecific alkaline phosphatase (TNAP), tethered to the outer leaflet of osteoblast and chondrocyte membranes, cleaves extracellular inorganic pyrophosphate (PPi)—a potent physicochemical inhibitor of mineralization—into inorganic phosphate (Pi). In rickets and osteomalacia, osteoblasts massively upregulate TNAP expression in a compensatory attempt to lower local PPi and elevate local Pi, explaining the dramatic elevations of serum ALP observed in clinical practice.

4. Natural History

The natural progression of unmineralized skeletal matrix differs markedly between pediatric patients with open growth plates and skeletally mature adults.

Pediatric Rickets: Skeletal and Extraskeletal Evolution

Untreated pediatric rickets progresses along a chronological trajectory corresponding to mechanical loading and skeletal growth spurts:

• Early Infancy (0 to 6 Months): The earliest clinical sign is craniotabes, characterized by soft, compressible parieto-occipital cranial bones that yield with a “ping-pong ball” sensation under gentle digital pressure. Delayed anterior fontanelle closure (persisting beyond 18 to 24 months), frontal bossing (“caput quadratum” or Olympian brow), and squarish head contours emerge. Severe infantile hypocalcemia may trigger laryngeal stridor, neuromuscular excitability, carpopedal tetany, and generalized seizures.
• Thoracic Progression (6 to 12 Months): Unmineralized costochondral junctions expand symmetrically, producing the palpable and visible “rachitic rosary”. Dynamic diaphragmatic traction on softened lower rib cages pulls the ribs inward during inspiration, forming a transverse subcostal depression termed Harrison’s groove, accompanied by anterior sternal protrusion (pectus carinatum).
• Ambulatory Toddlers (1 to 3 Years): As children transition to standing and walking, softened long bones buckle under gravitational load. Prominent expansion of the distal radius and ulna produces knobby wrist enlargement. Mechanical axis deviation produces progressive genu varum (bowing of the distal femur and proximal tibia), internal tibial torsion, and coxa vara.
• Late Childhood and Adolescence: If untreated, deformities transition to severe genu valgum, windswept deformities, anterior tibial bowing (“saber shin”), pelvic flattening, kyphoscoliosis, and disproportionate short stature with shortened limbs. In XLH, spontaneous periapical dental abscesses develop in structurally normal teeth without preceding caries due to abnormal dentin mineralization and enlarged pulp chambers.

Adult Osteomalacia: Chronic Progression and Fragility

Adult osteomalacia presents an insidious, indolent natural history, frequently remaining undiagnosed or misclassified as fibromyalgia, polymyalgia rheumatica, axial spondyloarthritis, or senile osteoporosis for several years:

• Diffuse Osseous Pain: Patients suffer from a persistent, deep, aching bone pain localized to the lumbar spine, pelvic ring, proximal femurs, ribs, and scapulae. The pain is exacerbated by weight-bearing, direct percussion, and physical activity.
• Proximal Motor Myopathy: Severe hypophosphatemia and secondary hyperparathyroidism impair calcium handling in skeletal muscle sarcoplasmic reticulum, generating profound pelvic girdle and quadriceps muscle weakness. Patients experience difficulty climbing stairs or rising from low seats without arm support, adopting a wide-based, rolling “waddling” gait.
• Insufficiency Pseudofractures (Looser Zones): Incomplete cortical stress fractures form along lines of mechanical stress. In untreated disease, these pseudofractures fail to bridge with mineralized callus and progress to complete, displaced fractures following minor low-energy trauma (most commonly subtrochanteric femur and femoral neck fractures).
• Permanent Skeletal Deformities: Chronic axial loading leads to severe thoracic kyphosis, bell-shaped thoracic collapse, and inward acetabular protrusion (protrusio acetabuli) producing a narrowed, “triradiate” (trefoil) pelvic inlet that historically caused obstructed labor in pregnant women. In adult XLH, widespread enthesopathy develops, causing extensive spinal ligament ossification, facet ankylosis, and severe peripheral arthrosis.

5. Clinical Presentation

Accurate clinical diagnosis requires focused diagnostic history-taking and structured, provocative physical examination maneuvers.

History

Key historical inquiries must systematically explore dietary intake, environmental exposure, gastrointestinal function, pharmacotherapy, and family pedigree:

• Dietary and Infancy History: Duration of exclusive breastfeeding without daily 400 IU oral vitamin D supplementation; timing and composition of weaning foods; dairy and bioavailable calcium intake; strict vegan, macrobiotic, or restrictive elimination diets.
• Sun Exposure and Demographics: Latitude of residence; daily outdoor sun exposure; consistent use of broad-spectrum sunscreens; cultural or religious garments covering virtually all skin surfaces (e.g., purdah, burqa); skin phototype (dark skin pigmentation [Fitzpatrick types V and VI] requires up to 3 to 6 times longer UVB exposure to synthesize equivalent vitamin D compared to pale skin).
• Gastrointestinal and Hepatorenal Review: Chronic diarrhea, floating foul-smelling stools (steatorrhea), postprandial bloating; prior bariatric operations (Roux-en-Y gastric bypass, biliopancreatic diversion); celiac disease, Crohn’s disease, cystic fibrosis; chronic cholestatic liver disease (biliary atresia, primary biliary cholangitis); chronic renal insufficiency.
• Pharmacotherapy Exposure: Chronic treatment with cytochrome P450-inducing anticonvulsants (phenytoin, carbamazepine, phenobarbital), which accelerate hepatic conversion of 25(OH)D and calcitriol into inactive metabolites; antiretrovirals (tenofovir disoproxil fumarate, causing Fanconi syndrome); high-dose etidronate; recent intravenous iron infusions (ferric carboxymaltose, which provokes acute intact FGF23 elevations).
• Genetic and Family Pedigree: Short stature, leg bowing, early walking delay, spontaneous tooth abscesses without caries in first-degree relatives; parental consanguinity.

Physical Exam

Provocative examination maneuvers should be executed sequentially, recording objective sensitivity and specificity metrics:

• Chvostek Sign: Light digital percussion of the facial nerve trunk immediately anterior to the external auditory meatus and inferior to the zygomatic arch -> Unilateral twitching of facial muscles, specifically the corner of the mouth (orbicularis oris) and alae nasi [Sensitivity 28%, Specificity 96% for acute hypocalcemia].
• Trousseau Sign: Inflation of a standard sphygmomanometer cuff on the upper arm to 20 mmHg above systolic blood pressure, maintained for 3 minutes -> Elicitation of carpal spasm characterized by wrist and metacarpophalangeal flexion, interphalangeal extension, and thumb adduction (“main d’accoucheur”) [Sensitivity 94%, Specificity 99% for latent hypocalcemia].
• Timed Chair Stand Test (Gowers-Type Proximal Myopathy Maneuver): The patient is asked to rise from a standard 45-cm armless chair with arms folded across the chest -> Inability to rise without pushing off with hands against knees or thighs, indicating pelvic girdle and quadriceps muscle weakness [Sensitivity 88%, Specificity 78% for osteomalacic proximal myopathy].
• Osseous Percussion and Compression Test: Direct, firm thumb pressure or light percussion applied over the anterior mid-shaft of the tibia, sternal body, and bilateral iliac crests -> Immediate, exquisite, localized deep bone tenderness at sites of unmineralized osteoid accumulations or subclinical Looser zones [Sensitivity 85%, Specificity 84%].
• Wrist Metaphyseal Prominence Assessment: Palpation and circumferential caliper measurement of the distal radial and ulnar metaphyses -> Palpable widening, dorsal knobby prominence, and transverse cuffing exceeding 2 standard deviations above age-matched normative pediatric values [Sensitivity 92%, Specificity 90% for active pediatric rickets].
• Intercondylar and Intermalleolar Distance Measurement: In a standing weight-bearing position, measuring the intercondylar distance (ICD) with medial malleoli touching, or measuring the intermalleolar distance (IMD) with medial femoral condyles touching -> ICD >5 cm confirms pathological genu varum; IMD >7.5 cm confirms pathological genu valgum requiring formal long-leg mechanical axis alignment imaging [Sensitivity 87%, Specificity 91%].

6. Imaging and Diagnostic Studies

Diagnostic evaluation relies on plain radiographic signatures, comprehensive laboratory profiling, advanced functional nuclear imaging, and quantitative bone histomorphometry.

Radiographic Evaluation

Initial imaging must obtain full-length standing hip-to-ankle lower extremity radiographs (teleoroentgenograms) and dedicated AP views of bilateral wrists and knees:

• Pediatric Rachitic Metaphyseal Signatures: Cupping (concave depression and excavation of the metaphyseal margin abutting the physis), flaring (transverse widening and trumpet-shaped lateral expansion of the metaphysis), fraying (brush-like loss of the sharp line of provisional calcification), and physeal widening (substantial expansion of the radiolucent gap between epiphysis and metaphysis representing uncalcified hypertrophic chondrocytes).
• Adult Osteomalacic Signatures: Pathognomonic Looser zones (Milkman pseudofractures) consisting of narrow, transverse radiolucent bands (2 to 5 mm wide) perpendicular to the cortex with sclerotic margins along the medial femoral neck, medial subtrochanteric shaft, pubic rami, scapular border, and ribs; diffuse demineralization with coarsened primary stress trabeculae; and axial deformities including biconcave “codfish” vertebrae and a triradiate pelvic configuration.
• Radiographic Signs of Healing: Reappearance of a dense, transverse, mineralized line of provisional calcification across the metaphyseal gap within 2 to 4 weeks of initiating medical therapy, followed by progressive remodeling of the flared metaphyseal cortex over 6 to 12 months.

Laboratory Evaluation

Biochemical differentiation between calcipenic and phosphopenic etiologies requires a complete metabolic panel:

• Total and Ionized Calcium: Low or low-normal in calcipenic rickets; strictly normal in uncomplicated phosphopenic rickets (XLH, TIO).
• Serum Inorganic Phosphate: Low in both conditions during active disease. In calcipenic rickets, hypophosphatemia is secondary to PTH-induced phosphaturia; in phosphopenic rickets, hypophosphatemia is primary, severe, and persistent. Age-specific reference ranges must be utilized (pediatric normal: 4.0 to 7.0 mg/dL; adult normal: 2.5 to 4.5 mg/dL).
• Alkaline Phosphatase (ALP): Universally elevated in active rickets and osteomalacia. Total ALP serves as the most sensitive and cost-effective clinical marker for monitoring therapeutic remineralization.
• Intact Parathyroid Hormone (PTH): Markedly elevated in calcipenic rickets (often 2- to 10-fold above normal limits); normal or only minimally elevated in phosphopenic rickets (XLH).
• 25-Hydroxyvitamin D [25(OH)D]: Diagnostic benchmark for nutritional/environmental deficiency (<20 ng/mL defines deficiency; <12 ng/mL defines severe deficiency). Normal in genetic rickets (XLH, VDDR1A, VDDR2A).
• 1,25-Dihydroxyvitamin D [1,25(OH)2D]: Undetectable in VDDR1A; markedly elevated in VDDR2A; inappropriately normal or frankly low in XLH, ADHR, and TIO relative to the profound hypophosphatemia. In nutritional rickets, 1,25(OH)2D is frequently normal or elevated due to intense PTH stimulation, making it an unreliable test for diagnosing vitamin D deficiency.
• Tubular Maximum Reabsorption of Phosphate per GFR (TmP/GFR): Calculated from fasting morning simultaneous urine and serum phosphate and creatinine measurements using the Walton-Bijvoet nomogram. A depressed TmP/GFR (<2.5 mg/dL or <0.8 mmol/L in adults) in the presence of hypophosphatemia confirms renal phosphate wasting.
• Intact Fibroblast Growth Factor 23 (iFGF23): Markedly elevated or inappropriately “normal” in XLH, ADHR, ARHR, and TIO. Circulating levels are low or suppressed in calcipenic rickets and hereditary hypophosphatemic rickets with hypercalciuria (HHRH).

Advanced Functional Imaging and Histomorphometry

Specialized diagnostic modalities are reserved for tumor localization and definitive tissue confirmation:

• 68Ga-DOTATATE PET-CT: The gold standard imaging modality for localizing occult phosphaturic mesenchymal tumors (PMTs) in Tumor-Induced Osteomalacia. PMTs consistently overexpress somatostatin receptor subtype 2A (SSTR2A). 68Ga-DOTATATE PET-CT provides superior sensitivity (95% to 100%) and spatial resolution compared to 111In-octreotide SPECT or 18F-FDG PET-CT for detecting diminutive, subcentimeter tumors hidden within deep craniofacial bones or distal soft-tissue crevices.
• Dual-Energy X-Ray Absorptiometry (DXA): Demonstrates marked reductions in areal Bone Mineral Density (BMD) with disproportionately low Z-scores. DXA severely underestimates true bone mass in osteomalacia because it measures hydroxyapatite attenuation, mistaking unmineralized osteoid for bone loss.
• Tetracycline-Labeled Transiliac Crest Bone Biopsy: The definitive histomorphometric reference standard for osteomalacia. Administered as two separate oral tetracycline pulses (e.g., 3 days on, 10 days off, 3 days on). Undecalcified histological sections demonstrate osteoid volume/bone volume >10%, osteoid surface >20%, osteoid seam thickness >14 µm, mineralization lag time >100 days, and blurred or completely absent dual fluorochrome lines under ultraviolet light.

7. Classification

Rickets and osteomalacia are classified etiologically into Calcipenic and Phosphopenic categories based on primary biochemical pathways, genetic mutations, and targeted management protocols:

8. Treatment

Management of rickets and osteomalacia requires a coordinated multidisciplinary approach combining aggressive metabolic medical normalization with judicious, precisely timed orthopaedic intervention.

Medical / Nonoperative

Medical pharmacotherapy represents the primary foundation of treatment and must be individualized according to the underlying biochemical mechanism:

• Nutritional Calcipenic Rickets Protocol: Oral cholecalciferol (vitamin D3) 2,000 to 5,000 IU/day for 8 to 12 weeks, followed by maintenance therapy of 400 to 1,000 IU/day; or single-dose “stoss” therapy (100,000 to 300,000 IU) divided over 1 to 2 days for non-compliant settings. Elemental calcium (30 to 50 mg/kg/day divided three times daily) must be administered concurrently during the initial 4 to 8 weeks to prevent hungry bone syndrome.
• Vitamin D-Dependent Rickets Protocols: VDDR Type 1A requires lifelong oral calcitriol (0.25 to 1.0 µg/day) plus supplemental calcium. VDDR Type 2A requires massive oral calcium (3 to 6 g/day) and supraphysiological calcitriol (up to 10 to 20 µg/day), with nocturnal central venous calcium infusions reserved for total receptor resistance.
• X-Linked Hypophosphatemia Targeted Biologic Therapy: Burosumab (Crysvita), a fully human IgG1 monoclonal antibody targeting intact FGF23, dosed subcutaneously at 0.8 mg/kg every 2 weeks in children (titrated up to 2.0 mg/kg, max 90 mg) and 1.0 mg/kg every 4 weeks in adults (max 90 mg). Burosumab directly increases TmP/GFR and calcitriol synthesis, achieving superior rickets healing and linear growth without causing hypercalciuria or nephrocalcinosis.
• XLH Conventional Therapy: Oral elemental phosphate (Joulie solution or sodium/potassium phosphate tablets, 20 to 40 mg/kg/day divided into 4 to 6 daily doses) combined with oral calcitriol (20 to 40 ng/kg/day divided twice daily), requiring frequent renal ultrasounds and urinary calcium surveillance to prevent nephrocalcinosis and secondary hyperparathyroidism.
• Tumor-Induced Osteomalacia Protocol: Wide surgical excision of the phosphaturic mesenchymal tumor is curative, with rapid normalization of serum phosphate and FGF23 within 24 to 48 hours. When the tumor is unresectable or occult, burosumab is indicated.
• Role of Orthoses and Bracing: Routine prescription of knee-ankle-foot orthoses (KAFO) in toddlers with bowing deformities has fallen out of favor. Biomechanical and clinical trials demonstrate that rigid bracing does not accelerate angular correction beyond what is achieved by metabolic remineralization alone, and may induce disuse osteopenia and restricted mobility.

Operative

Surgical intervention is indicated to correct severe, symptomatic skeletal malalignment and stabilize structural pseudofractures once metabolic compensation has been achieved:

• Guided Growth (Temporary Hemiepiphysiodesis): Indicated in skeletally immature patients with persistent, significant angular deformities (mechanical axis deviation in Zone 2 or 3) and open physes, following full metabolic normalization. Extra-periosteal tension-band plates (e.g., non-rigid 8-plates) secured with non-locking epiphyseal and metaphyseal screws are placed spanning the convex side of the physis. This restrains longitudinal growth across the convex physis while uninhibited concave growth gradually corrects the mechanical axis at approximately 0.5° to 1.0° per month. Plates must be removed promptly when neutral alignment is achieved to prevent overcorrection.
• Corrective Osteotomies: Indicated in skeletally mature adolescents or adults, or children with severe multi-apical deformities (>15° to 20° angulation) unresponsive to guided growth. Rigid, load-sharing reamed intramedullary nails (or telescoping Fassier-Duval rods in growing children) are strongly preferred over plate-and-screw constructs, as surface plates create severe stress risers in metabolic bone predisposing to peri-implant fractures and screw cut-out. Acute correction is reserved for mild-to-moderate angular deformities (20°), large rotational abnormalities, or concurrent leg-length discrepancies, gradual correction utilizing circular external fixators (e.g., Taylor Spatial Frame) is mandatory to protect neurovascular structures and avoid traction injury to the common peroneal nerve.
• Stabilization of Looser Zones and Insufficiency Fractures: Looser zones of the femoral neck or subtrochanteric femur that fail to consolidate with medical therapy and exhibit progressive cortical widening represent impending complete fractures. Prophylactic stabilization with a reamed, cephalomedullary reconstruction nail or long locked femoral nail is indicated.

Indications & Contraindications

Definitive objective thresholds govern surgical decision-making in metabolic bone disease:

• Absolute Surgical Contraindications: Elective corrective osteotomy or guided growth must NEVER be performed in the presence of active, metabolically uncompensated disease (elevated ALP, active hypophosphatemia, uncalcified physes, or secondary hyperparathyroidism). Operating through unmineralized osteoid guarantees catastrophic nonunion, hardware failure, and rapid recurrence of deformity. Acute hypocalcemia or severe hypercalciuria also presents life-threatening perioperative cardiac and renal risks.
• Prerequisites for Surgical Clearance: Normal serum alkaline phosphatase, calcium, phosphate, and intact PTH sustained for a minimum of 3 to 6 consecutive months; plain radiographs confirming full reconstitution of the dense transverse line of provisional calcification, crisp cortical margins, and resolution of metaphyseal fraying.
• Objective Surgical Indications: Mechanical Axis Deviation (MAD) falling into Zone 2 or Zone 3 of the tibial plateau (>10 mm medial or lateral to knee center); intermalleolar distance >7.5 cm or intercondylar distance >5 cm persisting after 12 to 18 months of complete metabolic control; coronal deformity >15° in children >4 years of age; intractable mechanical pain, patellar maltracking, or joint instability; and completed or mechanically impending insufficiency fractures of the femoral neck, subtrochanteric shaft, or tibia.

9. Outcome

Clinical outcomes in rickets and osteomalacia depend on timely medical intervention, the patient’s remaining growth potential, and strict avoidance of premature surgical realignment.

Biochemical and Radiographic Remineralization Timelines

Following appropriate medical replacement therapy, biochemical markers resolve in a predictable chronological sequence:

• Electrolyte Normalization (Days 3 to 14): Serum calcium and phosphate levels typically normalize within 1 to 2 weeks of initiating therapy.
• PTH Suppression (Weeks 2 to 4): Secondary hyperparathyroidism resolves over 2 to 4 weeks as calcium-sensing receptor signaling is restored.
• Alkaline Phosphatase Kinetics (Months 1 to 6): Serum ALP may exhibit a brief transient increase during the initial 2 weeks due to accelerated osteoblast matrix synthesis, followed by a steady, exponential decline toward normal over 3 to 6 months. Normalization of ALP confirms that unmineralized osteoid volume has been cleared.
• Physeal Reconstitution (Weeks 2 to 12): Radiographic reappearance of the dense transverse line of provisional calcification occurs within 2 to 4 weeks. Metaphyseal cupping, fraying, and physeal widening completely resolve on plain radiographs over 6 to 12 months.

Skeletal Remodeling Potential and Surgical Durability

Long-term anatomical and functional outcomes vary substantially based on patient age and disease etiology:

• Spontaneous Remodeling in Toddlers: Young children (<3 to 4 years old) with nutritional calcipenic rickets and mild-to-moderate genu varum (<15°) exhibit substantial spontaneous remodeling capacity once metabolic healing is established. The majority achieve normal mechanical alignment within 12 to 24 months without orthopaedic surgical intervention.
• Persistent Deformities in Genetic Rickets: Patients with XLH or children diagnosed after age 5 have limited spontaneous remodeling potential. Severe coronal bowing and coxa vara typically persist, predisposing to accelerated unicompartmental osteoarthritis in adulthood if uncorrected.
• Guided Growth Durability: In metabolically controlled pediatric cohorts, temporary hemiepiphysiodesis with tension-band plates achieves successful angular correction in 85% to 92% of extremities. However, rebound deformity occurs in 15% to 30% of patients after hardware removal if metabolic control deteriorates or substantial longitudinal growth remains.
• Osteotomy Union Rates: Corrective osteotomies stabilized with locked intramedullary nails in metabolically quiescent bone achieve primary union rates >95%, with mean union times of 8 to 12 weeks. In stark contrast, osteotomies performed through active, unmineralized rachitic or osteomalacic bone suffer nonunion and delayed union rates exceeding 35% to 50%, with frequent hardware cut-out.

10. Complications

Complications associated with rickets and osteomalacia encompass acute metabolic decompensation, chronic medical adverse effects, and devastating orthopaedic hardware failures:

11. Pearls and Pitfalls

Mastery of metabolic bone disease demands acute diagnostic vigilance and strict avoidance of surgical timing errors.

Diagnostic Pearls and Pitfalls

• The Indispensable Screening Biomarker: Serum alkaline phosphatase (ALP) is the single most sensitive, cost-effective screening and monitoring tool. A normal age-adjusted ALP reliably excludes active, decompensated rickets or osteomalacia.
• The 1,25(OH)2D Diagnostic Trap: In nutritional vitamin D deficiency, serum 1,25(OH)2D levels are frequently normal or paradoxically elevated due to intense secondary hyperparathyroidism stimulating renal CYP27B1. Clinicians must never rely on 1,25(OH)2D to diagnose nutritional deficiency; serum 25(OH)D is the sole definitive diagnostic standard.
• Adult Osteomalacia Is the Great Mimicker: Any adult presenting with diffuse, aching bone pain, proximal muscle weakness, and symmetric cortical fissures on radiographs must be screened with ALP, calcium, phosphate, and 25(OH)D. Dismissing these patients as having fibromyalgia or simple osteoporosis leads to years of debilitating, unnecessary suffering.
• The Calcium Co-Administration Mandate: Never administer high-dose vitamin D or calcitriol to a patient with severe calcipenic rickets without simultaneous oral calcium supplementation. Rapid uptake of circulating calcium into the unmineralized skeleton will trigger precipitous, life-threatening hypocalcemia (hungry bone syndrome).
• Avoid Blind Surgical Exploration in TIO: Never perform blind surgical exploration for an occult phosphaturic mesenchymal tumor based on anatomical suspicion alone. PMTs are frequently diminutive (subcentimeter) and located in unexpected sites. Obtain high-resolution 68Ga-DOTATATE PET-CT and confirm with selective venous sampling before taking the patient to the operating room.

Operative Pearls and Pitfalls

• The Six-Month Quiescence Rule: Elective corrective osteotomy must be deferred until serum ALP, calcium, phosphate, and PTH have remained within normal physiological limits for a minimum of 6 consecutive months, and plain radiographs demonstrate a crisp, continuous line of provisional calcification.
• Load-Sharing Intramedullary Fixation: When performing corrective osteotomies in metabolic bone disease, always select locked intramedullary nails or telescoping rods. Rigid surface plates create severe stress concentrations at screw-plate junctions in softened bone, predisposing to catastrophic peri-implant fractures.
• Prophylactic Peroneal Nerve Decompression: During acute surgical correction of severe genu valgum exceeding 15°, perform a formal open decompression of the common peroneal nerve at the fibular neck to prevent traction neuropraxia.
• Do Not Plate Looser Zones: Never mistake a Looser zone for an acute traumatic fracture and attempt compression plating without medical remineralization. Looser zones consist of unmineralized osteoid and will not unite until the underlying metabolic defect is corrected.
• Tension-Band Plate Position: When performing guided growth for genu varum or valgum, place tension-band plates extra-periosteally directly across the center of the physis under fluoroscopic guidance. Avoid inserting screws across the perichondrial ring of LaCroix to prevent permanent physeal arrest.

12. Controversy

Modern clinical practice in metabolic orthopaedics faces several evolving controversies surrounding medical vs. surgical intervention, novel biological agents, and drug-induced pathologies.

Guided Growth versus Corrective Osteotomy Timing

While guided growth (temporary hemiepiphysiodesis) provides a minimally invasive outpatient procedure that avoids the morbidity of osteotomy, its efficacy in children with genetic rickets (such as XLH) remains actively debated. Rachitic physes exhibit unpredictable growth rates and high rates of rebound deformity (up to 30%) following hardware extraction. Some pediatric orthopaedic surgeons advocate deferring surgical realignment until near skeletal maturity to perform definitive multi-level osteotomies with intramedullary fixation. Conversely, proponents of early guided growth emphasize that correcting the mechanical axis early prevents abnormal joint wear, relieves ligamentous laxity, and optimizes longitudinal growth potential.

Burosumab versus Conventional Calcitriol and Phosphate

Level I randomized clinical trials have conclusively demonstrated that burosumab achieves superior rickets healing, greater linear height velocity, and direct normalization of renal phosphate reabsorption compared to conventional oral phosphate and calcitriol therapy, while completely eliminating the risk of therapy-induced nephrocalcinosis. However, the astronomical annual cost of burosumab ($200,000 to $400,000 per patient per year) presents severe health-economic and resource-allocation dilemmas. Significant controversy surrounds whether burosumab should be continued indefinitely into adult life in patients whose physes have closed and who lack active pseudofractures or debilitating bone pain.

Localization and Management of Occult PMTs in TIO

In tumor-induced osteomalacia, surgical resection of the phosphaturic mesenchymal tumor cures the metabolic defect. However, identifying the offending neoplasm can be exceptionally challenging. Diminutive PMTs may measure only a few millimeters and reside in inaccessible anatomical sites, such as the skull base, masticator space, or plantar fascia. When 68Ga-DOTATATE PET-CT and selective venous sampling fail to identify a definitive lesion, or when tumors are surgically unresectable, debate centers on whether to manage patients with long-term burosumab therapy versus targeted peptide receptor radionuclide therapy (PRRT with 177Lu-DOTATATE) directed at tumor somatostatin receptors.

Intravenous Iron-Induced Hypophosphatemic Osteomalacia

Landmark randomized trials have exposed a major iatrogenic cause of phosphopenic osteomalacia: intravenous iron formulations containing carbohydrate shells that inhibit physiological FGF23 degradation, predominantly ferric carboxymaltose (FCM). FCM administration triggers rapid, profound, and sustained elevations in intact FGF23, resulting in severe renal phosphate wasting and symptomatic osteomalacia with insufficiency fractures in patients receiving repeated infusions. Significant debate exists among hematologists, nephrologists, and orthopaedic surgeons regarding routine biochemical phosphate monitoring and the comparative safety of alternative IV iron formulations (such as ferumoxytol and iron isomaltoside/derisomaltose) that do not trigger FGF23 elevation.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Wolf M, Chertow GM, Macdougall IC et al. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018. doi:10.1172/jci.insight.124486 [Level I: Randomized Controlled Trial]
• Insogna KL, Briot K, Imel EA et al. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone Miner Res. 2018. doi:10.1002/jbmr.3475 [Level I: Randomized Controlled Trial]
• Rendina D, Abate V, Cacace G et al. Tumor-induced Osteomalacia: A Systematic Review and Individual Patient’s Data Analysis. J Clin Endocrinol Metab. 2022. doi:10.1210/clinem/dgac253 [Level I: Systematic Review / Meta-Analysis]
• A. Catharine Ross, JoAnn E. Manson, Steven A. Abrams et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. The Journal of Clinical Endocrinology & Metabolism. 2010. doi:10.1210/jc.2010-2704 [Level V (Expert Conceptual Review): Seminal Conceptual / Observational Study]
• Michael F. Holick. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. American Journal of Clinical Nutrition. 2004. doi:10.1093/ajcn/80.6.1678s [Level V (Expert Conceptual Review): Seminal Conceptual / Observational Study]

15. Master Class Pro-Tip

The cardinal sin in metabolic orthopaedics is operating on a moving target. Corrective osteotomy performed during active rickets or unmineralized osteomalacia is a predictable recipe for disaster: screws strip in uncalcified osteoid, plates create catastrophic stress risers, and the underlying biological defect guarantees delayed union, nonunion, or rapid deformity recurrence. Enforce the Six-Month Quiescence Rule with absolute discipline: verify that serum alkaline phosphatase has normalized to baseline, intact PTH and phosphate are physiological, and plain radiographs demonstrate a crisp, continuous line of provisional calcification. When correction is undertaken in skeletally mature patients, choose intramedullary load-sharing rods over surface plates, and during acute valgus corrections exceeding 15 degrees, always decompress the common peroneal nerve at the fibular neck to avert devastating traction neuropraxia.

Master Class Surgical Pearl: Metabolic Bone Disease and Deformity Correction